Member: RADAR on Specialty Pharmacy

Specialty Pharmacies Have Many Roles to Play During Outbreak

April 1, 2020

As the COVID-19 pandemic continues its assault on the globe and the U.S. passes 12,000 deaths from it, all eyes are on the health care industry. While the public looks to pharma manufacturers for potential treatments and vaccines, labs for testing to detect the virus, and providers and others in their realm for being on the front line of the defense against it, specialty pharmacies still have a vital role to play.

To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.

Manufacturers Can Assist Other Stakeholders in COVID Battle

April 1, 2020

As the new coronavirus continues its spread, pharma companies are finding themselves facing a spate of challenges. And although they’ll need to find ways to counter those setbacks, they also can help address issues facing other health care industry stakeholders.

To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.

Sarclisa Is Likely to Be Managed At Parity With Similar Drugs

With Chart: Payers covering 70% of lives are unlikely to require patients currently on Pomalyst + dexamethasone (Pd) to switch to isatuximab + Pd

April 1, 2020

On March 2, the FDA approved Sanofi’s Sarclisa (isatuximab-irfc) for the treatment of multiple myeloma, a hematologic malignancy. The move added another therapy to a class full of products, both indicated for the condition and used off label. Almost half of payers responding to a Zitter Insights survey said they anticipate their company will manage the new treatment on parity with other multiple myeloma drugs that have a similar indication.

To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.

CVS Enters Deal to Purchase, Rebrand Schnucks Pharmacies

April 1, 2020

CVS Pharmacy is expanding its co-branding efforts through a recently unveiled deal with Schnuck Markets Inc. by which it will acquire the company’s retail and specialty pharmacy businesses.

To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.

New FDA Approvals

April 1, 2020

✦ March 9: The FDA approved Acacia Pharma Group plc’s Barhemsys (amisulpride) for the prevention of postoperative nausea and vomiting in adults either alone or with an antiemetic of a different class and treatment of PONV in adults who have received antiemetic prophylaxis with an agent of a different class or who have not received prophylaxis. Dosing for prevention of PONV is 5 mg via an intravenous injection over one to two minutes at the time of induction of anesthesia and 10 mg in the event of nausea and/or vomiting after a surgical procedure. The company says it expects the product to be available in the second half of this year. Visit https://barhemsys.com.

To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.